This Phase I Clinical trial will test the safety, tolerability and pharmacokinetics of Bod’s proprietary Ecs315 extract presented as a sublingual wafer. A positive trial outcome will leave the Company with a unique, patent protected, standardised and reproducible cannabis product which maybe sold or licenced to major pharmaceutical companies.Perhaps following this trial there should be a 'proof of concept' Phase 1b for a specific condition, possibly targeting the autism spectrum (?) and possibly leading to an IND application with the FDA (?).
- Forums
- ASX - By Stock
- BOD
- Ann: Trial ready Cannabis Sublingual Wafer Formulation complete
Ann: Trial ready Cannabis Sublingual Wafer Formulation complete, page-2
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add BOD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable